| Date Filed | Type | Description |
| 10/05/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/03/2023 |
4
| INCON Co., Ltd. (10% Owner) has filed a Form 4 on ZyVersa Therapeutics, Inc. |
| 07/26/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/26/2023 |
POS EX
| Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]: |
| 07/19/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/18/2023 |
SC 13G
| L1 Capital Global Opportunities Master Fund, Ltd. reports a 8.6% stake in ZyVersa Therapeutics, Inc. |
| 07/07/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 06/30/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 05/19/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/19/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/12/2023 |
SC 13D/A
| Glover Stephen C. reports a 6.8% stake in ZyVersa Therapeutics, Inc. |
| 05/12/2023 |
SC 13D/A
| O'Connor Daniel J. reports a 7.7% stake in ZyVersa Therapeutics, Inc. |
| 05/12/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/28/2023 |
424B4
| Form 424B4 - Prospectus [Rule 424(b)(4)]: |
| 04/28/2023 |
POS EX
| Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]: |
| 04/27/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/03/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| Oaktree Capital Group, LLC reports a 0% stake in Zyversa Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| A.G.P. / ALLIANCE GLOBAL PARTNERS CORP. reports a 8.9% stake in ZYVERSA THERAPEUTICS, INC. |
| 02/14/2023 |
SC 13G/A
| Lighthouse Investment Partners, LLC reports a 0% stake in Larkspur Health Acquisition Corp. |
| 02/14/2023 |
SC 13G
| INCON Co., Ltd. reports a 16.5% stake in ZyVersa Therapeutics, Inc. |
| 02/13/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 01/31/2023 |
SC 13G/A
| Yakira Capital Management, Inc. reports a 0% stake in Larkspur Health Acquisition Corp. |
|